Source: Virtual Congress 2021 – Advances in asthma treatment



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hopkins (London, United Kingdom), J. Han (Norfolk, VA, United States of America), V. Lund (London, United Kingdom), C. Bachert (Ghent, Belgium), Z. Diamant (Leuven, Belgium), W. Fokkens (Amsterdam, Netherlands), A. Sousa (London, United Kingdom), S. Smith (Research Triangle Park, NC, United States of America), S. Yang (Collegeville, PA, United States of America), B. Mayer (London, United Kingdom), S. Yancey (Research Triangle Park, NC, United States of America), R. Chan (London, United Kingdom), S. Lee (Pittsburgh, PA, United States of America). Late Breaking Abstract - Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria. 3536

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Determinants of disease control in patients with severe COPD. The CLAVE Study Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Detection of clinical instability by eNose in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Late Breaking Abstract - Characteristics of T2-biomarker low severe asthma patients in the UK Severe Asthma Registry (UKSAR) Source: International Congress 2019 – Asthma epidemiology in the 21st century Year: 2019 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Promising results of the infliximab biosimilar Inflectra® in severe sarcoidosis patients Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Adherence to GOLD recommendations in Italian patients with COPD categorised as frequent and non-frequent exacerbators: The MISTRAL study Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Real-world evidence of dual bronchodilator therapy using Clinical COPD Questionnaire in 4700 COPD patients Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010